The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Long-term side effects of glucocorticoids
Abstract
INTRODUCTION: Glucocorticoids represent the standard therapy for reducing inflammation and immune activation in various diseases. However, as with any potent medication, they are not without side effects. Glucocorticoid-associated side effects may involve most major organ systems. Musculoskeletal, gastrointestinal, cardiovascular, endocrine, neuropsychiatric, dermatologic, ocular, and immunologic side effects are all possible. AREAS COVERED: This article analyzes English-language literature and provides an update on the most recent literature regarding side effects of systemic glucocorticoid treatment. EXPERT OPINION: The risk/benefit ratio of glucocorticoid therapy can be improved by proper use. Careful monitoring and using appropriate preventive strategies can potentially minimize side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
Use of Inhaled Corticosteroids and Risk of Fractures
Van Staa, T. P., Leufkens, H. G. M., & Cooper, C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.581 · Cited by 1,308
Use of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Gabriel, S. E., Jaakkimainen, L., & Bombardier, C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-10-787 · Cited by 1,237
Hench, P. S., Kendall, E. C., Slocumb, C. H., & Polley, H. F. (1949) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00526-3 · Cited by 1,179
Risk of Infectious Complications in Patients Taking Glucocorticosteroids
Stuck, A. E., Minder, C. E., & Frey, F. J. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.6.954 · Cited by 836
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730
Haugeberg, G., Uhlig, T., Falch, J. A., Halse, J. I., & Kvien, T. K. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200003)43:3<522::aid-anr7>3.0.co;2-y · Cited by 687
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1496::aid-art271>3.0.co;2-5 · Cited by 647
Cardiac Steatosis in Diabetes Mellitus: A 1 H-Magnetic Resonance Spectroscopy Study
McGavock, J. M., Lingvay, I., Zib, I., Tillery, T., Salas, N., Unger, R., Levine, B. D., Raskin, P., Victor, R. G., & Szczepaniak, L. S. (2007) · Circulation · doi:10.1161/circulationaha.106.645614 · Cited by 612 · cited 1×
“[32] Moreover, accumulation of triglycerides in the myocardium can lead to impaired left ventricular filling dynamics.[34] Systemic glucocorticoids may induce”
BackgroundCorticosteroid Use and Peptic Ulcer Disease: Role of Nonsteroidal Anti-inflammatory Drugs
Piper, J. M., Ray, W. A., Daugherty, J. R., & Griffin, M. R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-735 · Cited by 608
Dose-related patterns of glucocorticoid-induced side effects
Huscher, D., Thiele, K., Gromnica-Ihle, E., Hein, G., Demary, W., Dreher, R., Zink, A., & Buttgereit, F. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092163 · Cited by 604 · cited 3×
“Musculoskeletal Osteoporosis,[7–13] Avascular necrosis of bone, [14,15] Myopathy [16,17] Endocrine and Metabolic Hyperglycemia,[18,19] Diabetes mellitus,[18,19] Dyslipidemia [20,21] Weight gain, Cushingoid features,[22] Growth suppression,[23] Adrenal suppression [24] Gastrointestinal Gastritis, Peptic ulcer, Gastroin…”
BackgroundPopulation‐based assessment of adverse events associated with long‐term glucocorticoid use
Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., Kovac, S. H., Spettell, C. M., & Saag, K. G. (2006) · Arthritis Care & Research · doi:10.1002/art.21984 · Cited by 595
Steroid-induced psychiatric syndromes
Lewis, D. A., & Smith, R. E. (1983) · Journal of Affective Disorders · doi:10.1016/0165-0327(83)90022-8 · Cited by 528
Da Silva, J. A. P., Jacobs, J. W. G., Kirwan, J. R., Boers, M., Saag, K. G., Inês, L. B. S., de Koning, E. J. P., Buttgereit, F., Cutolo, M., Capell, H., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.038638 · Cited by 522
Mechanisms of glucocorticoid-induced myopathy
Schakman, O., Gilson, H., & Thissen, J. P. (2008) · Journal of Endocrinology · doi:10.1677/joe-07-0606 · Cited by 521
HENCH, P. S. (1950) · Archives of Internal Medicine · doi:10.1001/archinte.1950.00230100002001 · Cited by 501
Souverein, P. C., Berard, A., Van Staa, T. P., Cooper, C., Egberts, A. C. G., Leufkens, H. G. M., & Walker, B. R. (2004) · Heart · doi:10.1136/hrt.2003.020180 · Cited by 482
Risk factors for central serous chorioretinopathy
Haimovici, R., Koh, S., Gagnon, D. R., Lehrfeld, T., & Wellik, S. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2003.09.024 · Cited by 475
Glucocorticoid-induced osteonecrosis
Weinstein, R. S. (2012) · Endocrine · doi:10.1007/s12020-011-9580-0 · Cited by 428
Hoes, J. N., Jacobs, J. W. G., Boers, M., Boumpas, D., Buttgereit, F., Caeyers, N., Choy, E. H., Cutolo, M., Da Silva, J. A. P., Esselens, G., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.072157 · Cited by 411
Effects of glucocorticoids on carbohydrate metabolism
Mcmahon, M., Gerich, J., & Rizza, R. (1988) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610040105 · Cited by 390 · cited 4×
“Musculoskeletal Osteoporosis,[7–13] Avascular necrosis of bone, [14,15] Myopathy [16,17] Endocrine and Metabolic Hyperglycemia,[18,19] Diabetes mellitus,[18,19] Dyslipidemia [20,21] Weight gain, Cushingoid features,[22] Growth suppression,[23] Adrenal suppression [24] Gastrointestinal Gastritis, Peptic ulcer, Gastroin…”
BackgroundInfluentialGlucocorticoid-Induced Osteoporosis and Osteonecrosis
Weinstein, R. S. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.004 · Cited by 364
Hippocampal Remodeling and Damage by Corticosteroids Implications for Mood Disorders
Brown, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00054-8 · Cited by 335
Acute adverse reactions to prednisone in relation to dosage
Program, T. B. C. D. S. (1972) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1972135part1694 · Cited by 335
Corticosteroids and peptic ulcer: meta‐analysis of adverse events during steroid therapy
CONN, H. O., & POYNARD, T. (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00855.x · Cited by 312
Fractures after rheumatoid arthritis a population‐based study
Hooyman, J. R., Joseph Melton, L., Nelson, A. M., Michael O'Fallon, W., & Lawrence Riggs, B. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780271205 · Cited by 283
Corticosteroid-induced clinical adverse events: frequency, risk factors and patient?s opinion
Fardet, L., Flahault, A., Kettaneh, A., Tiev, K. P., Généreau, T., Tolédano, C., Lebbé, C., & Cabane, J. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07950.x · Cited by 273
Mood and Cognitive Changes During Systemic Corticosteroid Therapy
Brown, E. S., & Chandler, P. A. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0104 · Cited by 269
Systemic Glucocorticoid Therapy: a Review of its Metabolic and Cardiovascular Adverse Events
Fardet, L., & Fève, B. (2014) · Drugs · doi:10.1007/s40265-014-0282-9 · Cited by 236
The Etiology of Steroid Cataract
James, E. R. (2007) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2006.0067 · Cited by 236
Dermatoporosis: A Chronic Cutaneous Insufficiency/Fragility Syndrome
Kaya, G., & Saurat, J.-H. (2007) · Dermatology · doi:10.1159/000107621 · Cited by 234
Corticosteroids and Glaucoma Risk
Tripathi, R. C., Parapuram, S. K., Tripathi, B. J., Zhong, Y., & Chalam, K. (1999) · Drugs & Aging · doi:10.2165/00002512-199915060-00004 · Cited by 228
Schäcke, H., Berger, M., Rehwinkel, H., & Asadullah, K. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.014 · Cited by 223
Steroids: pharmacology, complications, and practice delivery issues.
Ericson-Neilsen, W., & Kaye, A. D. (2014) · PubMed Central · Cited by 199
van der Goes, M. C., Jacobs, J. W. G., Boers, M., Andrews, T., Blom-Bakkers, M. A. M., Buttgereit, F., Caeyers, N., Cutolo, M., Da Silva, J. A. P., Guillevin, L., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.124958 · Cited by 194
Pathophysiology of Dyslipidemia in Cushing’s Syndrome
Arnaldi, G., Scandali, V. M., Trementino, L., Cardinaletti, M., Appolloni, G., & Boscaro, M. (2010) · Neuroendocrinology · doi:10.1159/000314213 · Cited by 189
Corticosteroids and the Risk of Atrial Fibrillation
van der Hooft, C. S., Heeringa, J., Brusselle, G. G., Hofman, A., Witteman, J. C. M., Kingma, J. H., Sturkenboom, M. C. J. M., & Stricker, B. H. C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.9.1016 · Cited by 176
van der Goes, M. C., Jacobs, J. W. G., & Bijlsma, J. W. J. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4686 · Cited by 162
Quan, L., Zhang, Y., Crielaard, B. J., Dusad, A., Lele, S. M., Rijcken, C. J. F., Metselaar, J. M., Kostková, H., Etrych, T., Ulbrich, K., et al. (2014) · ACS Nano · doi:10.1021/nn4048205 · Cited by 160
Resistance exercise prevents glucocorticoid-induced myopathy in heart transplant recipients
Braith, R. W., Welsch, M. A., Mills, R. M., KELLER, J. W., & Pollock, M. L. (1998) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-199804000-00003 · Cited by 157
Corticosteroids and Infectious Diseases
Dale, D. C., & Petersdorf, R. G. (1973) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)32228-3 · Cited by 142
Effects of glucocorticoids on carbohydrate metabolism
Olefsky, J. M., & Kimmerling, G. (1976) · The American Journal of the Medical Sciences · doi:10.1097/00000441-197603000-00009 · Cited by 137
Hench, P. S. (1949) · Mayo Clinic Proceedings · Cited by 135
Sadr‐Azodi, O., Mattsson, F., Bexelius, T. S., Lindblad, M., Lagergren, J., & Ljung, R. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2737 · Cited by 105
Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
de Nijs, R. N. J. (2008) · PubMed · Cited by 87
Glucocorticoid-induced osteoporosis in rheumatic diseases
Pereira, R. M. R., de Carvalho, J. F., & CANALIS, E. M. (2010) · Clinics · doi:10.1590/s1807-59322010001100024 · Cited by 77
Choi, H. K., & Seeger, J. D. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21329 · Cited by 74
Sato, A., Funder, J. W., Okubo, M., Kubota, E., & Saruta, T. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00149-j · Cited by 60
Indications et complications des corticoïdes en ophtalmologie
Fel, A., Aslangul, E., & Jeunne, C. L. (2012) · La Presse Médicale · doi:10.1016/j.lpm.2012.02.001 · Cited by 55
Corticosteroids and Functions in the Anterior Segment of the Eye
Miller, D., Peczon, J. D., & Whitworth, C. G. (1965) · American Journal of Ophthalmology · doi:10.1016/0002-9394(65)95015-4 · Cited by 55
Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures
Gourlay, M. L., Franceschini, N., & Sheyn, Y. (2006) · Clinical Rheumatology · doi:10.1007/s10067-006-0315-1 · Cited by 50
Reuter, K. C., Grunwitz, C. R., Kaminski, B. M., Steinhilber, D., Radeke, H. H., & Stein, J. M. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183947 · Cited by 44
Daens, S., Peretz, A., Maertelaer, V. D., Moris, M., & Bergmann, P. (1999) · Osteoporosis International · doi:10.1007/s001980050227 · Cited by 40
Enhancement of the Ocular Therapeutic Effect of Prednisolone Acetate by Liposomal Entrapment
Elbialy, N. S., Abdol-Azim, B. M., Shafaa, M. W., shazly, L. H. E., Elshazly, A. H. M., & Khalil, W. A. (2013) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2013.1711 · Cited by 28
Corticoïdes et… infections, dopage, chirurgie et sexualité
Grossi, O., & Généreau, T. (2013) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2012.12.008 · Cited by 10
Cited by
American Society of Hematology 2019 guidelines for immune thrombocytopenia
Neunert, C., Terrell, D. R., Arnold, D. M., Buchanan, G., Cines, D. B., Cooper, N., Cuker, A., Despotovic, J. M., George, J. N., Grace, R. F., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000966 · Cited by 1,406
Emerging pharmaceutical therapies for osteoarthritis
Latourte, A., Kloppenburg, M., & Richette, P. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00518-6 · Cited by 418
Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights
De Sá Coutinho, D., Pacheco, M. T., Frozza, R. L., & Bernardi, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061812 · Cited by 290
Stern, A., Skalsky, K., Avni, T., Carrara, E., Leibovici, L., & Paul, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007720.pub3 · Cited by 271
M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization
Li, H., Feng, Y., Zheng, X., Jia, M., Mei, Z., Wang, Y., Zhang, Z., Zhou, M., & Li, C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.019 · Cited by 259
Metadata
- Authors
- Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H., & Foster, C. S.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2016-02-06
- Volume
- 15
- Issue
- 4
- Pages
- 457-465
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2274841233
- Cited by
- 869
- References
- 56
- FWCI
- 21.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.